MTC-A4

MTC-A4 is a preclinical-stage drug candidate developed by the Polish biotechnology company Biotts for the treatment of pain. The asset utilizes Biotts' proprietary Multilayer Transdermal Carrier (MTC) technology, a specialized delivery system designed to transport active pharmaceutical ingredients (APIs) through the skin barrier. The MTC platform is engineered to enhance drug permeability and bioavailability, potentially allowing for controlled release and reduced systemic toxicity compared to traditional administration routes. While the specific active ingredient of MTC-A4 has not been publicly identified, it is part of a broader pipeline of transdermal analgesics that includes formulations of buprenorphine (MTC-A1) and fentanyl (MTC-A3).